Can needles ease Post-Surgery bladder troubles? a trial puts electroacupuncture to the test

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients with benign prostatic hyperplasia (BPH) who have undergone transurethral resection of the prostate (TURP) or holmium laser enucleation of the prostate (HoLEP); 2. Aged between 50 and 85 years; 3. Provided signed informed consent. Exclusion Criteria: 1. Pathological examination results confirm the presence of prostatic tumors; 2. History of lower urinary tract cancers including prostate cancer and bladder cancer within the past 5 years; 3. Currently receiving or have received treatments based on principles similar to acupuncture within 6 months prior to enrollment, such as electroacupuncture, warm moxibustion, and warm needling moxibustion; 4. Presence of uncontrolled urinary system infection before surgery (asymptomatic lower urinary tract infection is excluded); 5. Diagnosed with severe cardiac conditions including severe arrhythmia, severe cardiac insufficiency, acute myocarditis, constrictive pericarditis, pericardial tamponade, severe valvular heart disease, and heart failure; 6. Confirmed liver injury or potentially severe liver disease (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level \> 10 times the upper limit of normal); 7. Confirmed severe renal impairment (estimated glomerular filtration rate (eGFR) \< 25 mL/min/1.73m²), scheduled for or currently undergoing dialysis, or diagnosed with acute contrast-induced nephropathy during screening; 8. Confirmed severe primary diseases such as dysfunction of other vital organs or diseases of the hematopoietic system; 9. Confirmed coagulation dysfunction (with definite clinical diagnosis or clear laboratory test results); 10. Patients with mental illness or cognitive impairment; patients with severe depression, alcohol dependence, or a history of drug abuse; 11. Patients considered unsuitable for participation in this study by the investigators, or patients with factors strongly associated with study dropout, such as frequently changing working environments that increase the risk of loss to follow-up; 12. Survival period estimated to be ≤ 6 months by the investigators; 13. Currently participating in other clinical trials.